Drug updated on 11/13/2023
|Injection (intradermal/subcutaneous/subareolar/peritumoral; 92.5 MBq (2.5 mCi) and 250 mcg of technetium Tc 99m tilmanocept)
|Radioactive diagnostic agents
| Ongoing and
- Indicated with or without scintigraphic imaging for lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in adult and pediatric patients age one month and older with solid tumors for which this procedure is a component of intraoperative management.
- Indicated with or without scintigraphic imaging for lymphatic guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.
Product Monograph / Prescribing Information
|Lymphoseek (technetium Tc 99m tilmanocept) Prescribing Information.
|Cardinal Health 414, LLC Dublin, OH
Systematic Reviews / Meta-Analyses
|99mTc-Tilmanocept performance for sentinel node mapping in breast cancer, melanoma, and head and neck cancer: a systematic review and meta-analysis from a European expert panel.
|European Journal of Nuclear Medicine and Molecular Imaging